A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)

Shanghai University of TCM0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Real-time fluorescent RT-PCR detection of new coronavirus nucleic acid positive, or viral gene sequencing is highly homologous with known new coronavirus;
•2. Confirmed as a novel coronavirus pneumonia common and severe patients, meets the diagnostic criteria of the novel coronavirus pneumonia diagnosis and treatment plan (trial implementation of the sixth edition)
•3. aged 18 to 65 years;
•4. Learn about the significance of the study before the trial also the possible inconveniences and potential risk.

•1. Patients with mild and critical novel coronavirus pneumonia;
•2. Acute respiratory disease caused by non- novel coronavirus pneumonia;
•3. Patients with diabetes and hypertension accompanied by severe primary immunodeficiency disease acquired immunodeficiency syndrome congenital respiratory malformation congenital heart disease pulmonary dysplasia and other diseases;
•4. Patients with obvious abnormal heart, liver and kidney disease or serious other system diseases such as digestive system urogenital system blood system hemorrhagic disease central nervous system psychiatric diseases in acute stage, and endocrine and metabolic diseases;
•5. People who are known to be allergic to the ingredients in the research drug, or patients with allergies;
•6. Women who are breastfeeding, pregnant, or have a positive urine pregnancy test;
•7. Patients who are participating in other clinical trials or patients who have participated in other drug clinical trials within 1 month;
•8. Researchers find the patient inappropriate to be involved in the trial.

发起方

Shanghai University of TCM